High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia.
暂无分享,去创建一个
C. Flamant | G. Leverger | M. Labopin | C. Preudhomme | Aline Renneville | L. Douay | P. Ballerini | J. Landman-Parker | F. Mazingue | A. Auvrignon | H. Lapillonne | J. Lai | C. Pérot | M. Adam | S. Fasola | A. Blaise | A. Dehée | Françoise Bellman
[1] A. Baruchel,et al. Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit – multicenter studies of the French LAME (Leucémie Aiguë Myéloblastique Enfant) Cooperative Group , 2005, Leukemia.
[2] W. Hiddemann,et al. Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia , 2005, Leukemia.
[3] S. Feig,et al. Postremission therapy for children with acute myeloid leukemia: the children's cancer group experience in the transplant era , 2005, Leukemia.
[4] J. Downing,et al. Gene Expression Profiling of Pediatric Acute Myelogenous Leukemia Materials and Methods , 2022 .
[5] E. Kjeldsen,et al. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients – results from a single‐centre study , 2004, British journal of haematology.
[6] A. Baruchel,et al. Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] D. Hémon,et al. Incidence of childhood leukaemia and non-Hodgkin's lymphoma in France: National Registry of Childhood Leukaemia and Lymphoma, 1990–1999 , 2004, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.
[8] A. Baruchel,et al. Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89/91 protocol of the French Society of Pediatric Hematology and Immunology. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] F. Watzinger,et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer program , 2003, Leukemia.
[10] W. Hiddemann,et al. New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts. , 2003, Blood.
[11] K. Tobal,et al. Prognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemia , 2003, British journal of haematology.
[12] J. Radich,et al. Monitoring bcr-abl by polymerase chain reaction in the treatment of chronic myeloid leukemia , 2003, Current oncology reports.
[13] B. Johansson,et al. Cytogenetic abnormalities in childhood acute myeloid leukaemia: a Nordic series comprising all children enrolled in the NOPHO‐93‐AML trial between 1993 and 2001 , 2003, British journal of haematology.
[14] K. Livak,et al. Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129. , 2003, Blood.
[15] N. Hosen,et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. , 2003, Blood.
[16] I. Bernstein,et al. Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. , 2002, Blood.
[17] D. Cilloni,et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients , 2002, Leukemia.
[18] O. Hrusak,et al. Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry , 2002, Leukemia.
[19] E. Thiel,et al. Quantitative real-time RT-PCR detects elevated Wilms tumor gene (WT1) expression in autologous blood stem cell preparations (PBSCs) from acute myeloid leukemia (AML) patients indicating contamination with leukemic blasts , 2002, Bone Marrow Transplantation.
[20] K. Wheatley,et al. Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia. , 2001, Blood.
[21] A. Órfão,et al. Minimal residual disease in leukaemia patients. , 2001, The Lancet. Oncology.
[22] F. Berthold,et al. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] J. Buckley,et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. , 2001, Blood.
[24] M. Horowitz,et al. Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission. , 2000, Blood.
[25] E. Macintyre,et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease , 1999, Leukemia.
[26] F. Behm,et al. Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 8821. , 1999, Blood.
[27] B. Kornhuber,et al. wt1 Gene Expression in Childhood Leukemias , 1999, Acta Haematologica.
[28] I. Bièche,et al. Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. , 1999, Clinical chemistry.
[29] G. Kong,et al. Expression of Wilms tumor gene (WT1) in children with acute leukemia. , 1999, Pediatric hematology and oncology.
[30] K Wheatley,et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. , 1998, Blood.
[31] Y. Oji,et al. Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells. , 1998, Blood.
[32] R. Gray,et al. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: results of the United Kingdom Medical Research Council's 10th AML trial , 1998 .
[33] U. Maurer,et al. High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. , 1997, Blood.
[34] G. Heinze,et al. Prognostic significance of WT1 gene expression at diagnosis in adult de novo acute myeloid leukemia , 1997, Leukemia.
[35] A. Baruchel,et al. Allogeneic bone marrow transplantation vs aggressive post-remission chemotherapy for children with acute myeloid leukemia in first complete remission. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP). , 1996, Bone marrow transplantation.
[36] T. Akiyama,et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. , 1994, Blood.
[37] R. Berger,et al. t( 12;21): A new recurrent translocation in acute lymphoblastic leukemia , 1994, Genes, chromosomes & cancer.
[38] J. Buckley,et al. Impact of high-dose cytarabine and asparaginase intensification on childhood acute myeloid leukemia: a report from the Childrens Cancer Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.